LEADER 02417nam 2200577 a 450 001 9910139631303321 005 20170815153718.0 010 $a1-283-17566-5 010 $a9786613175663 010 $a1-118-02366-8 010 $a1-118-02367-6 010 $a1-118-02365-X 035 $a(CKB)2550000000041121 035 $a(EBL)693249 035 $a(OCoLC)745970855 035 $a(SSID)ssj0000524794 035 $a(PQKBManifestationID)12222185 035 $a(PQKBTitleCode)TC0000524794 035 $a(PQKBWorkID)10488185 035 $a(PQKB)11413967 035 $a(MiAaPQ)EBC693249 035 $a(PPN)243334850 035 $a(EXLCZ)992550000000041121 100 $a20101020d2011 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aPharmaceutical anti-counterfeiting$b[electronic resource] $ecombating the real danger from fake drugs /$fMark Davison 210 $aHoboken, N.J. $cJohn Wiley & Sons$dc2011 215 $a1 online resource (428 p.) 300 $aDescription based upon print version of record. 311 $a0-470-61617-2 320 $aIncludes bibliographical references and index. 327 $apt. 1. General themes -- pt. 2. Authentication -- pt. 3. Product tracking -- pt. 4. Conclusions and the future -- pt. 5. Further Resources. 330 $aThis book overviews and integrates the business and technical issues that pharmaceutical companies need to know in order to combat the major global problem of counterfeit medicines. In addition to discussion of the problems, the author Davison addresses analytical techniques scientists use to detect counterfeits and presents some possible solutions to the threat of counterfeit medical products. Coverage moves from basic overview of the problem, costs / risks to consumers (toxic products, mistrust of drug companies) and business (revenue loss, public trust), government oversight and regulation, 606 $aProduct counterfeiting 606 $aDrug adulteration 615 0$aProduct counterfeiting. 615 0$aDrug adulteration. 676 $a615.1068/4 676 $a615.10684 700 $aDavison$b Mark$f1968 Mar. 1-$0983906 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910139631303321 996 $aPharmaceutical anti-counterfeiting$92246383 997 $aUNINA